Material and methods
Cancer
CANCER
This study was a single-arm phase II clinical trial (NCT02916511), which was initiated in 2016 and finished in 2018 at Fudan University Shanghai Cancer Center. The protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Center.